Journal of General Internal Medicine

, Volume 28, Issue 3, pp 399–405

Intentional Non-Adherence to Medications among HIV Positive Alcohol Drinkers: Prospective Study of Interactive Toxicity Beliefs

  • Seth C. Kalichman
  • Tamar Grebler
  • Christina M. Amaral
  • Megan McNerey
  • Denise White
  • Moira O. Kalichman
  • Chauncey Cherry
  • Lisa Eaton
Original Research

ABSTRACT

BACKGROUND

Antiretroviral therapy (ART) adherence is key to successful treatment of HIV infection and alcohol is a known barrier to adherence. Beyond intoxication, ART adherence is impacted by beliefs that mixing alcohol and medications is toxic.

PURPOSE

To examine prospective relationships of factors contributing to intentional medication non-adherence when drinking.

METHODS

People who both receive ART and drink alcohol (N = 178) were enrolled in a 12-month prospective cohort study that monitored beliefs about the hazards of mixing ART with alcohol (interactive toxicity beliefs), alcohol consumption using electronic daily diaries, ART adherence assessed by both unannounced pill counts and self-report, and chart-abstracted HIV viral load.

RESULTS

Participants who reported skipping or stopping their ART when drinking (N = 90, 51 %) demonstrated significantly poorer ART adherence, were less likely to be viral suppressed, and more likely to have CD4 counts under 200/cc3. Day-level analyses showed that participants who endorsed interactive toxicity beliefs were significantly more likely to miss medications on drinking days.

CONCLUSIONS

Confirming earlier cross-sectional studies, the current findings from a prospective cohort show that a substantial number of people intentionally skip or stop their medications when drinking. Interventions are needed to correct alcohol-related interactive toxicity misinformation and promote adherence among alcohol drinkers.

KEY WORDS

medication adherence alcohol use HIV treatment beliefs 

REFERENCES

  1. 1.
    Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008;3(7):e2783.PubMedCrossRefGoogle Scholar
  2. 2.
    Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45(3):372–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Hendershot CS, Stoner SA, Pantalone DW, et al. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52(2):180–202.PubMedCrossRefGoogle Scholar
  4. 4.
    Braithwaite RS, Kozal MJ, Chang CC, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS. 2007;21(12):1579–89.PubMedCrossRefGoogle Scholar
  5. 5.
    Braithwaite RS, McGinnis KA, Conigliaro J, et al. A temporal and dose–response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res. 2005;29(7):1190–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Aloisi MS, Arici C, Balzano R, et al. Behavioral correlates of adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S145–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Sankar A, Wunderlich T, Neufeld S, et al. Sero-positive African Americans’ beliefs about alcohol and their impact on anti-retroviral adherence. AIDS Behav. 2007;11(2):195–203.PubMedCrossRefGoogle Scholar
  8. 8.
    Kalichman SC, Amaral CM, White D, et al. Prevalence and clinical implications of interactive toxicity beliefs regarding mixing alcohol and antiretroviral therapies among people living with HIV/AIDS. AIDS Patient Care STDs. 2009;23(6):449–54.PubMedCrossRefGoogle Scholar
  9. 9.
    Neuman MG, Schneider M, Nanau RM, et al. HIV-antiretroviral therapy induced liver, gastrointestinal, and pancreatic injury. Int J Hepatol. 2012;2012:760706.PubMedGoogle Scholar
  10. 10.
    Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol. 2010;8(12):1002–12.PubMedCrossRefGoogle Scholar
  11. 11.
    Szabo G, Zakhari S. Mechanisms of alcohol-mediated hepatotoxicity in human-immunodeficiency-virus-infected patients. World J Gastroenterol. 2011;17(20):2500–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Paquette D, Bryant J, de Wit J. Respondent-driven sampling and the recruitment of people with small injecting networks. AIDS Behav. 2012;16(4):890–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Gribble JN, Miller HG, Cooley PC, et al. The impact of T-ACASI interviewing on reported drug use among men who have sex with men. Subst Use Misuse. 2000;35(6–8):869–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Morrison-Beedy D, Carey MP, Tu X. Accuracy of audio computer-assisted self-interviewing (ACASI) and self-administered questionnaires for the assessment of sexual behavior. AIDS Behav. 2006;10(5):541–52.PubMedCrossRefGoogle Scholar
  15. 15.
    Kalichman SC, Rompa D, Cage M. Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV-AIDS. J Nerv Ment Dis. 2000;188(10):662–70.PubMedCrossRefGoogle Scholar
  16. 16.
    Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption II. Addictions. 1993;88(6):791–804.CrossRefGoogle Scholar
  17. 17.
    Babor T, Higgins-Biddle J, Saunders J, et al. The Alcohol Use Disorders Identification Test: Guidelines for use inprimary Care. 2nd ed. Geneva: World Health Organization; 2001.Google Scholar
  18. 18.
    Maisto SA, Conigliaro J, McNeil M, et al. An empirical investigation of the factor structure of the AUDIT. Psychol Assess. 2000;12(3):346–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Altice F, Mostashari F, Friedland G. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:47–58.PubMedGoogle Scholar
  20. 20.
    Bangsberg DR, Hecht FM, Charlebois ED, et al. Comparing objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav. 2001;5:275–81.CrossRefGoogle Scholar
  21. 21.
    Kalichman SC, Amaral CM, Cherry C, et al. Monitoring Antiretroviral adherence by unannounced pill counts conducted by telephone: reliability and criterion-related validity. HIV Clin Trials. 2008;9:298–308.PubMedCrossRefGoogle Scholar
  22. 22.
    Kalichman SC, Amaral CM, Stearns HL, et al. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Intern Med. 2007;22:1003–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12(3):255–66.PubMedCrossRefGoogle Scholar
  24. 24.
    Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol. 1997;50(4):385–91.PubMedCrossRefGoogle Scholar
  25. 25.
    Simoni J, Kurth AE, Pearson C, et al. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10:227–331.PubMedCrossRefGoogle Scholar
  26. 26.
    Bernhardt JM, Usdan S, Mays D, et al. Alcohol assessment among college students using wireless mobile technology. J Stud Alcohol Drugs. 2009;70(5):771–5.PubMedGoogle Scholar
  27. 27.
    McAuliffe TL, DiFranceisco W, Reed BR. Low numeracy predicts reduced accuracy of retrospective reports of frequency of sexual behavior. AIDS Behav. 2010;14(6):1320–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Bangsberg D, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4:65–72.PubMedCrossRefGoogle Scholar
  29. 29.
    Li JZ, Paredes R, Ribaudo H, et al. Relationship between Minority NNRTI resistance mutations, adherence, and the risk of virologic failure. AIDS. 2011;26:185–92.CrossRefGoogle Scholar
  30. 30.
    Bangsberg DR, Deeks SG. Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med. 2002;17(10):812–3.PubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2012

Authors and Affiliations

  • Seth C. Kalichman
    • 1
  • Tamar Grebler
    • 1
  • Christina M. Amaral
    • 1
  • Megan McNerey
    • 1
  • Denise White
    • 1
  • Moira O. Kalichman
    • 1
  • Chauncey Cherry
    • 1
  • Lisa Eaton
    • 1
  1. 1.Department of PsychologyUniversity of ConnecticutStorrsUSA

Personalised recommendations